Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 2/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25492962 | 0.92 | NCF1 (0.41) | GNAO1GNAI3GNAI1KDM1AHRH3 | |
| SCHEMBL29324792 | 0.91 | CYP2D6 (0.38) | GNAO1KDM1AHRH3CYP2D6SLC6A4 | |
| SCHEMBL26743216 | 0.89 | HRH3 (0.45) | GNAO1KDM1AHRH3CYP2D6ACHE | |
| SCHEMBL26742225 | 0.88 | KDM1A (0.36) | GNAO1KDM1AHRH3CYP2D6SLC6A4 | |
| SCHEMBL29329947 | 0.88 | SLC6A4 (0.40) | GNAO1GNAI3GNAI1KDM1AHRH3 | |
| SCHEMBL29329914 | 0.87 | GNAO1 (0.39) | GNAO1GNAI3GNAI1HRH3NCF1 | |
| SCHEMBL26747096 | 0.84 | HRH3 (0.39) | GNAO1KDM1AHRH3CYP2D6SLC6A4 | |
| SCHEMBL26744662 | 0.84 | NPY1R (0.37) | GNAO1KDM1AHRH3CYP2D6SLC6A4 | |
| SCHEMBL26741830 | 0.84 | HRH3 (0.48) | GNAO1GNAI3GNAI1KDM1AHRH3 | |
| SCHEMBL20028304 | 0.83 | NCF1 (0.35) | KDM1ANCF1ACHECHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | GNAO1 1574/4885GNAI3 169/4885GNAI1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.